SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VERISANTE TECHNOLOGY

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: andre dallaire5/8/2013 2:14:05 PM
  Read Replies (1) of 254
 
Photonics.com article

Prism Winner Nabs Edison Award
VANCOUVER, British Columbia, Canada, May 8, 2013 — Skin cancer detector maker Verisante Technology Inc. received a bronze Edison Award in the Diagnostic/Analytic category for its noninvasive Aura device. The award was presented last month in Chicago.

In February, the Aura was selected as a 2013 Prism Award for photonics innovation winner by Photonics Media and SPIE in the Life Sciences and Biophotonics category (See: Prism Awards Honor Innovations in Photonics). The Aura won, in part, because it allows Raman-based disease detection to move into the doctor’s office for the first time, and, unlike other optical skin cancer detectors, it doesn’t use visual characteristics to assess lesions but instead images the biochemical changes in the skin (based on molecular vibrations) using a near-infrared (785 nm) laser. Click here for a video about the Aura's Prism Award win.

The Edison Awards, named after Thomas Alva Edison, are conducted by Edison Universe. Their purpose is to inspire creative minds to remain at the forefront of innovation, creativity and ingenuity in the global economy. The 2013 nominees were judged by a panel of more than 3000 leading business executives, including past winners, academics and leaders in product development, design, engineering, science and medicine, the organization said.

Aura's clinical study results, published last year in Cancer Research, showed that the device provides a significant advancement over current clinical diagnosis, Verisante said, with a 99 percent success rate in finding skin cancer and the potential to reduce unnecessary biopsies by 50 to 100 percent.

For more information, visit: www.edisonawards.com or www.verisante.com

http://www.photonics.com/Article.aspx?AID=53825

Read more at http://www.stockhouse.com/bullboards/messagedetail.aspx?p=0&m=32544901&l=0&r=0&s=VRS&t=LIST#5wQyAmtyWWFTuD3X.99
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext